Background: Chrysin is a natural flavonoid that exhibits various pharmacological activities including pain relief. However, the effects of chrysin on changes of metabolic profiles during pain remain unclear. The aim of this study was to analyze the biomarkers related to pain in serum and to evaluate the analgesic properties of chrysin in a rat model of pain. Methods: Male Wister rats were divided into four groups (n = 5). Pain was induced by injecting 50 μL of formalin into the hind paw. Chrysin and diclofenac (10 mg/kg, intraperitoneal injection) was administered to the intact and pain groups. All injections were given 30 minutes before pain induction. Immediately, the behavioral test was performed.Then the serum sample was separated for 1 HNMR-based metabolite analysis. Results: Chrysin treatment alleviated the paw licking events, flinching response, and pain score. The integrated analyses further revealed three major metabolic changes including glycine-serine-threonine, taurine-hypotaurine, and arginine by comparing the serums from intact operated rats, pain rats, and pain rats treated with chrysin, and suggested that chrysin may improve pain by regulating the biosynthesis of these metabolic pathways. Conclusions These findings provide insights into metabolic pathways involved in pain and the analgesic effects of chrysin and may help to identify potential targets for the anti-pain properties of chrysin.

Background: Chrysin is a natural flavonoid that exhibits various pharmacological activities including pain relief. However, the effects of chrysin on changes of metabolic profiles during pain remain unclear. The aim of this study was to analyze the biomarkers related to pain in serum and to evaluate the analgesic properties of chrysin in a rat model of pain. Methods: Male Wister rats were divided into four groups (n = 5). Pain was induced by injecting 50 μL of formalin into the hind paw. Chrysin and diclofenac (10 mg/kg, intraperitoneal injection) was administered to the intact and pain groups. All injections were given 30 minutes before pain induction. Immediately, the behavioral test was performed.Then the serum sample was separated for 1 HNMR-based metabolite analysis. Results: Chrysin treatment alleviated the paw licking events, flinching response, and pain score. The integrated analyses further revealed three major metabolic changes including glycine-serine-threonine, taurine-hypotaurine, and arginine by comparing the serums from intact operated rats, pain rats, and pain rats treated with chrysin, and suggested that chrysin may improve pain by regulating the biosynthesis of these metabolic pathways. Conclusions These findings provide insights into metabolic pathways involved in pain and the analgesic effects of chrysin and may help to identify potential targets for the anti-pain properties of chrysin.

Background: Chrysin is a natural flavonoid that exhibits various pharmacological activities including pain relief. However, the effects of chrysin on changes of metabolic profiles during pain remain unclear. The aim of this study was to analyze the biomarkers related to pain in serum and to evaluate the analgesic properties of chrysin in a rat model of pain. Methods: Male Wister rats were divided into four groups (n = 5). Pain was induced by injecting 50 μL of formalin into the hind paw. Chrysin and diclofenac (10 mg/kg, intraperitoneal injection) was administered to the intact and pain groups. All injections were given 30 minutes before pain induction. Immediately, the behavioral test was performed.Then the serum sample was separated for 1 HNMR-based metabolite analysis. Results: Chrysin treatment alleviated the paw licking events, flinching response, and pain score. The integrated analyses further revealed three major metabolic changes including glycine-serine-threonine, taurine-hypotaurine, and arginine by comparing the serums from intact operated rats, pain rats, and pain rats treated with chrysin, and suggested that chrysin may improve pain by regulating the biosynthesis of these metabolic pathways. Conclusions These findings provide insights into metabolic pathways involved in pain and the analgesic effects of chrysin and may help to identify potential targets for the anti-pain properties of chrysin.

Background: Chrysin is a natural flavonoid that exhibits various pharmacological activities including pain relief. However, the effects of chrysin on changes of metabolic profiles during pain remain unclear. The aim of this study was to analyze the biomarkers related to pain in serum and to evaluate the analgesic properties of chrysin in a rat model of pain. Methods: Male Wister rats were divided into four groups (n = 5). Pain was induced by injecting 50 μL of formalin into the hind paw. Chrysin and diclofenac (10 mg/kg, intraperitoneal injection) was administered to the intact and pain groups. All injections were given 30 minutes before pain induction. Immediately, the behavioral test was performed.Then the serum sample was separated for 1 HNMR-based metabolite analysis. Results: Chrysin treatment alleviated the paw licking events, flinching response, and pain score. The integrated analyses further revealed three major metabolic changes including glycine-serine-threonine, taurine-hypotaurine, and arginine by comparing the serums from intact operated rats, pain rats, and pain rats treated with chrysin, and suggested that chrysin may improve pain by regulating the biosynthesis of these metabolic pathways. Conclusions These findings provide insights into metabolic pathways involved in pain and the analgesic effects of chrysin and may help to identify potential targets for the anti-pain properties of chrysin.

Background: Chrysin is a natural flavonoid that exhibits various pharmacological activities including pain relief. However, the effects of chrysin on changes of metabolic profiles during pain remain unclear. The aim of this study was to analyze the biomarkers related to pain in serum and to evaluate the analgesic properties of chrysin in a rat model of pain. Methods: Male Wister rats were divided into four groups (n = 5). Pain was induced by injecting 50 μL of formalin into the hind paw. Chrysin and diclofenac (10 mg/kg, intraperitoneal injection) was administered to the intact and pain groups. All injections were given 30 minutes before pain induction. Immediately, the behavioral test was performed.Then the serum sample was separated for 1 HNMR-based metabolite analysis. Results: Chrysin treatment alleviated the paw licking events, flinching response, and pain score. The integrated analyses further revealed three major metabolic changes including glycine-serine-threonine, taurine-hypotaurine, and arginine by comparing the serums from intact operated rats, pain rats, and pain rats treated with chrysin, and suggested that chrysin may improve pain by regulating the biosynthesis of these metabolic pathways. Conclusions These findings provide insights into metabolic pathways involved in pain and the analgesic effects of chrysin and may help to identify potential targets for the anti-pain properties of chrysin.

Purpose: Neurogenic bladder dysfunction (NGB) has an impact on the quality of life, which made it an important research subject in preclinical studies. The present review investigates the effect of stem cell (SC) therapy on bladder functional recovery after the onset of spinal cord injury (SCI), multiple sclerosis (MS), Parkinson disease (PD), and stroke in rodent models. Methods: All experiments evaluated the regenerative potential of SC on the management of NGB in rodent models up to June 2019, were included. From 1,189 relevant publications, 20 studies met our inclusion criteria of which 15 were conducted on SCI, 2 on PD, 2 on stroke, and 1 on MS in the rodent models. We conducted a meta-analysis on SCI experiments and for other neurological diseases, detailed urodynamic findings were reported. Results: The common SC sources used for therapeutical purposes were neural progenitor cells, bone marrow mesenchymal SCs, human amniotic fluid SCs, and human umbilical cord blood SCs. There was a significant improvement of micturition pressure in both contusion and transaction SCI models 4 and 8 weeks post-SC transplantation. Residual urine volume, micturition volume, and bladder capacity were improved 28 days after SC transplantation only in the transaction model of SCI. Nonvoiding contraction recovered only in 56 days post-cell transplantation in the contusion model. Conclusions Partial bladder recovery has been evident after SC therapy in SCI models. Due to limitations in the number of studies in other neurological diseases, additional studies are necessary to confirm the detailed mechanism for bladder recovery.